RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Nonselective beta-adrenergic blocker (NSBB) therapy for the prevention of initial and recurrent gastrointestinal bleeding in cirrhotic patients with gastroesophageal varices has been used for the past four decades. NSBB therapy is considered the cornerstone of treatment for varices, and has become the standard of care. However, a 2010 study from the group that pioneered β-blocker therapy suggested a detrimental effect of NSBBs in decompensated cirrhosis, especially in patients with refractory ascites. Since then, numerous additional studies have incompletely resolved whether NSBBs are deleterious, although more recent evidence weighs against a harmful effect. The possibility of a “therapeutic window” has also been raised. We aimed to review the literature to analyze the pros and cons of using NSBBs in patients with cirrhosis, not only with respect to bleeding or mortality but also to other potential benefits and risks. β-blockers are highly effective in preventing first bleeding and recurrent bleeding. Furthermore, NSBBs improve congestion/ischemia of the gut mucosa, decrease intestinal permeability, and therefore indirectly alleviate systemic inflammation. β-blockers shorten the electrocardiographic prolonged QTc interval and may also decrease the incidence of hepatocellular carcinoma. On the other hand, the possibility of deleterious effects in cirrhosis has not been completely eliminated. NSBBs may be associated with an increased risk of portal vein thrombosis, although this could be correlational artifact. Overall, we conclude that β-blockers in cirrhosis are much more of a friend than enemy. (Clin Mol Hepatol 2021;27:425-436)

참고문헌 (Reference)

1 Villanueva C, "β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension(PREDESCI) : a randomised, double-blind, placebo-controlled, multicentre trial" 393 : 1597-1608, 2019

2 Mookerjee RP, "Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure" 64 : 574-582, 2016

3 Kumar M, "Treatment with carvedilol improves survival of patients with acute‑on‑chronic liver failure : a randomized controlled trial" 13 : 800-813, 2019

4 Liao X, "The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signaling" 24 : 1669-1676, 2010

5 Krag A, "The window hypothesis : haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease" 61 : 967-969, 2012

6 Herrera I, "The use of β-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis" 28 : 1194-1197, 2016

7 Sersté T, "The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis" 35 : 1974-1982, 2015

8 Cazzaniga M, "The systemic inflammatory response syndrome in cirrhotic patients : relationship with their in-hospital outcome" 51 : 475-482, 2009

9 Seo YS, "The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension" 18 : 337-346, 2012

10 Santeusanio AD, "The impact of cirrhosis and prescription medications on QTc interval before and after liver transplantation" 32 : 48-53, 2019